In addition to enhanced resolution, the uMR Jupiter 5T device reportedly addresses image uniformity and radiofrequency safety that have been previous challenges with ultra-high-field MRI.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the uMR Jupiter 5T system, the first ultra-high-field magnetic resonance imaging (MRI) system to gain clearance for full-body exams.
Equipped with an eight-channel whole-body multi-transmit system, the uMR Jupiter 5T system bolsters the clarity and detail of anatomical structures, according to United Imaging, the manufacturer of the device. The company said the 5T MRI system offers enhanced imaging capabilities for the heart, abdomen and pelvis that will facilitate improved diagnostic precision.
Reportedly the first ultra-high-field magnetic resonance imaging (MRI) system to gain FDA clearance for full-body exams, the uMR Jupiter 5T system offers enhanced imaging capabilities for the heart, abdomen and pelvis that may facilitate improved diagnostic precision. (Image courtesy of United Imaging.)
In addition to improved visualization of challenging anatomical regions, United Imaging noted that the device’s design and technology address previous issues associated with ultra-high-field MRI by ensuring radiofrequency safety and consistent imaging quality.
“We have always prioritized innovation that can make a broad clinical impact. Because it is aimed first and foremost at bringing ultra-high-field into greater clinical use, we believe (the uMR Jupiter 5T system) will have an exciting impact across our industry, and for clinical patients across the globe who have never had access to ultra-high-field in the past,” noted Jeffrey M. Bundy, Ph.D., the president and chief commercial officer of United Imaging in North America.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.